Clinical Trial Update: Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection [Phase 3]

View source ↗

Summary

A Phase 3 trial investigated the efficacy and safety of sofusbuvir/velpatasvir (SOF/VEL) fixed-dose combination and SOF/VEL/voxilaprevir (SOF/VEL/VOX) in adults…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Sofosbuvir/Velpatasvir (sofosbuvir/velpatasvir)
• Sofosbuvir/Velpatasvir/Voxilaprevir (sofosbuvir/velpatasvir/voxilaprevir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2021-10-27